

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity: CHEMGENEX PHARMACEUTICALS LIMITED</b>
<b>ABN: 79 000 248 304</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Elmar Schnee
<b>Date of last notice</b>	13 May 2009

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	24,057,922 ordinary fully paid shares (CXS) held by Merck Santé;
<b>Date of change</b>	22 October 2010
<b>No. of securities held prior to change</b>	24,057,922 ordinary fully paid shares (CXS); 40,000 ordinary fully paid shares (CXS) held directly; 250,000 unlisted options exercisable at \$1.22 held directly
<b>Class</b>	Ordinary fully paid shares (CXS)
<b>Number acquired</b>	N/A
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	24,057,922 ordinary fully paid shares (CXS); 40,000 ordinary fully paid shares (CXS) held directly; 250,000 unlisted options exercisable at \$1.22 held directly
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Mr Elmar Schnee is a Director of Merck Santé which has signed an option agreement with Cephalon International Holdings, Inc (Cephalon), granting Cephalon an option over 22,131,962 ordinary shares at the price of A\$0.70 per share. The option expires on the later of (a) 31 March 2011; and (b) one week after the delivery by ChemGenex to Cephalon of the duly completed final tables, lists and figures document in relation to clinical studies CML-202 and CML-203.  A copy of the option agreement is attached to the substantial shareholder notice lodged by Cephalon.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A



J. A. Campbell  
 Company Secretary  
 22 October 2010

+ See chapter 19 for defined terms.